What medical technology company did Boston Scientific announce plans to acquire for $14.5 billion in January 2026?

In a significant move within the medical technology sector, Boston Scientific announced its intention to acquire Penumbra for approximately $14.5 billion in January 2026. This major transaction highlights the ongoing strategic consolidation within the healthcare industry as companies seek to expand their portfolios and market reach in high-growth areas.

Penumbra, a California-based medical device company, is renowned for its innovative technologies in the vascular and neurovascular spaces. Their products are crucial for treating conditions such as ischemic stroke, pulmonary embolism, and deep vein thrombosis, primarily through mechanical thrombectomy devices designed to remove blood clots. This specialized expertise makes Penumbra a valuable asset, allowing Boston Scientific to re-enter and significantly bolster its presence in these critical and rapidly expanding segments of the medical device market.

The acquisition is expected to complement Boston Scientific's existing cardiovascular offerings, which include a range of interventional devices. By integrating Penumbra's highly differentiated portfolio, Boston Scientific aims to enhance its ability to provide comprehensive solutions for patients suffering from complex vascular conditions. The deal, structured as a mix of cash and stock, also reflects Boston Scientific's strategy to accelerate its growth and reinforce its position as a leader in global healthcare innovation.